Initially there was no specific way to reverse the the the the the the the the the the anticoagulant effect of dabigatran in the event of of of of of of of of of of a major bleeding event, unlike for warfarin, but a a a a a a a a a a dabigatran antidote (idarucizumab) was approved by the FDA in 2015.